乳腺癌区域淋巴结照射采用容积旋转调强放疗后的超声心动图功能结局
这项前瞻性研究纳入19例接受容积旋转调强放疗(VMAT)辅助区域淋巴结照射(RNI)的乳腺癌患者,在放疗前、放疗结束时和放疗后6个月进行超声心动图检查。放疗后6个月左心室射血分数(LVEF)和整体纵向应变(GLS)均无显著下降,且与平均和最大心脏剂量无相关性。作者认为VMAT可能是需要RNI患者心脏规避的合理方法。
要点
- 19例可评估患者中,放疗前与放疗后6个月平均LVEF分别为61.8%和62.7%(P = .493),无显著下降。
- 平均GLS放疗前为-19.3%,放疗后6个月为-19.6%(P = .627),无显著变化。
- LVEF或GLS变化与平均或最大心脏剂量均无相关性(所有P > .1)。
核心结论
- 在这有限队列中,左侧RNI采用VMAT未观察到LVEF和GLS等超声心动图心脏功能参数的显著早期下降。
- 没有患者出现显著LVEF变化,也没有患者出现GLS持续下降。
- 作者认为VMAT可能是需要RNI患者(包括接受蒽环类和HER2靶向治疗者)心脏规避的合理方法。
- 需要更大样本量和更长随访来验证这些发现。
研究设计与样本
- 前瞻性研究,纳入接受VMAT辅助RNI的局部区域乳腺癌患者,经IRB批准。
- 共19例可评估患者,中位年龄38岁。
- 在放疗前、放疗结束时和放疗后6个月进行超声心动图检查,由单一读者测量。
- 放疗前后测量值采用符号秩检验比较,超声参数随时间变化与平均和最大心脏剂量采用Spearman相关检验比较。
主要发现
- 89%(n = 17)接受多柔比星,37%(n = 7)接受曲妥珠单抗/帕妥珠单抗联合治疗。
- 所有患者接受基于VMAT的全乳/胸壁和RNI照射。
- 平均平均心脏剂量为456 cGy(范围187-697 cGy),平均最大心脏剂量为3001 cGy(范围1560-4793 cGy)。
- 放疗前平均LVEF为61.8%(SD 4.4%),放疗后6个月为62.7%(SD 3.8%)(P = .493)。
- 放疗前平均GLS为-19.3%(SD 2.2%),放疗后6个月为-19.6%(SD 1.8%)(P = .627)。
临床怎么用
- 作者认为VMAT可能是需要RNI患者心脏规避的合理方法,包括接受蒽环类和HER2靶向治疗的患者。
- 作者指出需要更大样本量和更长随访来验证这些发现。
局限性
- 作者指出该研究为有限队列(limited cohort)。
- 作者指出需要更大样本量和更长随访来验证这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Regional nodal irradiation (RNI) for breast cancer yields improvements in disease outcomes, yet comprehensive target coverage often increases cardiac radiation therapy (RT) dose. Volumetric modulated arc therapy (VMAT) may mitigate high-dose cardiac exposure, although it often increases the volume of low-dose exposure. The cardiac implications of this dosimetric configuration (in contrast to historic 3D conformal techniques) remain uncertain. METHODS AND MATERIALS: Eligible patients receiving adjuvant RNI using VMAT for locoregional breast cancer were prospectively enrolled in an IRB-approved study. Echocardiograms were performed prior to RT, at the conclusion of RT, and 6 months following RT. Echocardiographic parameters were measured by a single reader and measures were compared pre- and post-RT via the signed-rank test. Changes in echocardiographic parameters over time were compared to mean and max heart doses via the Spearman correlation test. RESULTS: Among 19 evaluable patients (median age 38 years), 89% (n = 17) received doxorubicin and 37% (n = 7) received trastuzumab/pertuzumab combination therapy. All patients received VMAT-based whole-breast/chest wall and RNI. The average mean heart dose was 456 cGy (range, 187-697 cGy) and the average max heart dose was 3001 cGy (1560-4793 cGy). Among salient echocardiographic parameters, no significant decrement in cardiac function was observed when comparing pre-RT to 6 months post-RT: mean left ventricular ejection fraction (LVEF) was 61.8% (SD 4.4%) pre-RT and 62.7% (SD 3.8%) 6 months post-RT (P = .493); mean global longitudinal strain (GLS) was -19.3% (SD 2.2%) pre-RT and -19.6% (SD 1.8%) 6 months post-RT (P = .627). No individual patient exhibited reduced LVEF or sustained decrement in GLS. No correlations were observed for changes in LVEF or GLS when compared to mean or maximum heart doses (P > .1 for all). CONCLUSIONS: VMAT for left-sided RNI yielded no significant early decrement in echocardiographic parameters of cardiac function, including LVEF and GLS, within this limited cohort. No patient exhibited significant LVEF changes, and none exhibited sustained decrements in GLS. VMAT may be a reasonable approach to cardiac avoidance in patients requiring RNI, including those receiving anthracyclines and HER2-directed therapy. Larger cohorts with longer follow-ups will be needed to validate these findings.
引用
- Yu AF, White C, Zhang Z, et al. Echocardiographic Functional Outcomes Following Regional Nodal Irradiation for Breast Cancer Using Volumetric Modulated Arc Therapy. Adv Radiat Oncol. 2024. PMID: 39258142. doi:10.1016/j.adro.2024.101581
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。